The object of this retrospective study was to investigate the impact of targeted therapies on overall survival (OS), distant intracranial failure, local failure, and radiation necrosis among patients treated with radiation therapy for renal cell carcinoma (RCC) metastases to the brain.
All patients diagnosed with RCC brain metastasis (BM) between 1998 and 2015 at a single institution were included in this study. The primary outcome was OS, and secondary outcomes included local failure, distant intracranial failure, and radiation necrosis. The timing of targeted therapies was recorded. Multivariate Cox proportional-hazards regression was used to model OS, while multivariate competing-risks regression was used to model local failure, distant intracranial failure, and radiation necrosis, with death as a competing risk.
Three hundred seventy-six patients presented with 912 RCC BMs. Median OS was 9.7 months. Consistent with the previously validated diagnosis-specific graded prognostic assessment (DS-GPA) for RCC BM, Karnofsky Performance Status (KPS) and number of BMs were the only factors prognostic for OS. One hundred forty-seven patients (39%) received vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). Median OS was significantly greater among patients receiving TKIs (16.8 vs 7.3 months, p < 0.001). Following multivariate analysis, KPS, number of metastases, and TKI use remained significantly associated with OS.
The crude incidence of local failure was 14.9%, with a 12-month cumulative incidence of 13.4%. TKIs did not significantly decrease the 12-month cumulative incidence of local failure (11.4% vs 14.5%, p = 0.11). Following multivariate analysis, age, number of BMs, and lesion size remained associated with local failure. The 12-month cumulative incidence of radiation necrosis was 8.0%. Use of TKIs within 30 days of SRS was associated with a significantly increased 12-month cumulative incidence of radiation necrosis (10.9% vs 6.4%, p = 0.04).
Use of targeted therapies in patients with RCC BM treated with intracranial SRS was associated with improved OS. However, the use of TKIs within 30 days of SRS increases the rate of radiation necrosis without improving local control or reducing distant intracranial failure. Prospective studies are warranted to determine the optimal timing to reduce the rate of necrosis without detracting from survival.
Correspondence Samuel T. Chao: Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. firstname.lastname@example.org.
INCLUDE WHEN CITING Published online January 18, 2019; DOI: 10.3171/2018.8.JNS182100.
Disclosures Dr. Ahluwalia has direct stock ownership in Mimivax; has been a consultant for Monteris Medical, BMS, Astrazeneca, VBI Vacines, Abbvie, Varian, and Flatiron; and has received support from Novartis, Abbvie, Incyte, Astrazeneca, Novocure, Bayer, Merck, and Pharmacyclics for non–study-related clinical or research effort. Dr. Rini has received support from Pfizer for non–study-related clinical or research effort. Dr. Chao has received honorarium from Varian Medical System.
AnkerCJGrossmannKFAtkinsMBSunejaGTarhiniAAKirkwoodJM: Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys95:632–6462016
Barnholtz-SloanJSSloanAEDavisFGVigneauFDLaiPSawayaRE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol22:2865–28722004
BatesJEYounPPetersonCRIIIUsukiKYWalterKAOkunieffP: Radiotherapy for brain metastases from renal cell carcinoma in the targeted therapy era: the University of Rochester experience. Am J Clin Oncol40:439–4432017
CochranDCChanMDAkliluMLovatoJFAlphonseNKBourlandJD: The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J Neurosurg116:978–9832012
MagnusonWJYeungJTGuillodPDGettingerSNYuJBChiangVL: Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases. Int J Radiat Oncol Biol Phys95:673–6792016
MillerJABennettEEXiaoRKotechaRChaoSTVogelbaumMA: Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys96:1060–10692016
MotzerRJHutsonTETomczakPMichaelsonMDBukowskiRMOudardS: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol27:3584–35902009
ShawEScottCSouhamiLDinapoliRKlineRLoefflerJ: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys47:291–2982000
SheehanJPSunMHKondziolkaDFlickingerJLunsfordLD: Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg98:342–3492003
SneedPKMendezJVemer-van den HoekJGSeymourZAMaLMolinaroAM: Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg123:373–3862015
SolbergTDNearmanJMullinsJLiSBaranowska-KortylewiczJ: Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys72:918–9262008
SperdutoPWChaoSTSneedPKLuoXSuhJRobergeD: Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys77:655–6612010
SperdutoPWDeeganBJLiJJethwaKRBrownPDLockneyN: Effect of targeted therapies on prognostic factors, patterns of care, and survival in patients with renal cell carcinoma and brain metastases. Int J Radiat Oncol Biol Phys101:845–8532018
SternbergCNHawkinsREWagstaffJSalmanPMardiakJBarriosCH: A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer49:1287–12962013
TsaiYCHoPYTzenKYTuanTFLiuWLChengAL: Synergistic blockade of EGFR and HER2 by new-generation EGFR tyrosine kinase inhibitor enhances radiation effect in bladder cancer cells. Mol Cancer Ther14:810–8202015
WrónskiMMaorMHDavisBJSawayaRLevinVA: External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys37:753–7591997